Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Cady

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
BMC Neurology|June 6, 2022
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trialJessica Ailani, Peter McAllister, Paul K Winner, et al.
BMC Neurology|September 6, 2023
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trialJessica Ailani, Peter McAllister, Paul K Winner, et al.
Headache|June 15, 2005
Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraineKathleen A Foley, Roger Cady, Vincent Martin, et al.
Journal of the American Dietetic Association|July 1, 2008
Survey of retail milk composition as affected by label claims regarding farm-management practicesJohn Vicini, Terry Etherton, Penny Kris-Etherton, et al.
Headache|January 12, 2023
Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trialAmaal J Starling, Robert P Cowan, Dawn C Buse, et al.
The Journal of Headache and Pain|October 7, 2020
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) studyStephen Silberstein, Merle Diamond, Nada A Hindiyeh, et al.
Neurology|March 27, 2020
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2Richard B Lipton, Peter J Goadsby, Jeff Smith, et al.
Cephalalgia : an International Journal of Headache|October 27, 2010
Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID studyRichard B Lipton, Stephen Silberstein, David Dodick, et al.
The Lancet. Neurology|February 17, 2016
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trialHong Sun, David W Dodick, Stephen Silberstein, et al.
Journal of Neurology|August 24, 2023
Risk factors for migraine disease progression: a narrative review for a patient-centered approachRichard B Lipton, Dawn C Buse, Stephanie J Nahas, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
BMC Neurology|June 6, 2022
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trialJessica Ailani, Peter McAllister, Paul K Winner, et al.
BMC Neurology|September 6, 2023
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trialJessica Ailani, Peter McAllister, Paul K Winner, et al.
Headache|June 15, 2005
Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraineKathleen A Foley, Roger Cady, Vincent Martin, et al.
Journal of the American Dietetic Association|July 1, 2008
Survey of retail milk composition as affected by label claims regarding farm-management practicesJohn Vicini, Terry Etherton, Penny Kris-Etherton, et al.
Headache|January 12, 2023
Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trialAmaal J Starling, Robert P Cowan, Dawn C Buse, et al.
The Journal of Headache and Pain|October 7, 2020
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) studyStephen Silberstein, Merle Diamond, Nada A Hindiyeh, et al.
Neurology|March 27, 2020
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2Richard B Lipton, Peter J Goadsby, Jeff Smith, et al.
Cephalalgia : an International Journal of Headache|October 27, 2010
Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID studyRichard B Lipton, Stephen Silberstein, David Dodick, et al.
The Lancet. Neurology|February 17, 2016
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trialHong Sun, David W Dodick, Stephen Silberstein, et al.
Journal of Neurology|August 24, 2023
Risk factors for migraine disease progression: a narrative review for a patient-centered approachRichard B Lipton, Dawn C Buse, Stephanie J Nahas, et al.
Pageof 10